Insider Transactions in Q2 2025 at Ligand Pharmaceuticals Inc (LGND)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2025
|
Todd C Davis Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
233
+0.14%
|
$21,203
$91.08 P/Share
|
|
Jun 30
2025
|
Octavio Espinoza Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
224
+0.74%
|
$20,384
$91.08 P/Share
|
|
Jun 30
2025
|
Andrew Reardon CLO & Secretary |
BUY
Other acquisition or disposition
|
Direct |
233
+0.72%
|
$21,203
$91.08 P/Share
|
|
Jun 23
2025
|
Andrew Reardon CLO & Secretary |
SELL
Open market or private sale
|
Direct |
500
-1.54%
|
$57,000
$114.08 P/Share
|
|
Jun 10
2025
|
Andrew Reardon CLO & Secretary |
SELL
Open market or private sale
|
Direct |
500
-1.52%
|
$57,000
$114.54 P/Share
|
|
Jun 06
2025
|
Jason Aryeh Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+1.5%
|
-
|
|
Jun 06
2025
|
Nancy Ryan Gray Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+13.0%
|
-
|
|
Jun 06
2025
|
Jason Haas Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+15.47%
|
-
|
|
Jun 06
2025
|
John W Kozarich Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+2.49%
|
-
|
|
Jun 06
2025
|
Stephen L Sabba Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+3.45%
|
-
|
|
Jun 06
2025
|
Martine Zimmermann Director |
SELL
Payment of exercise price or tax liability
|
Direct |
188
-3.96%
|
$19,740
$105.99 P/Share
|
|
Jun 06
2025
|
Martine Zimmermann Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+20.3%
|
-
|
|
Jun 06
2025
|
John L Lamattina Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+3.79%
|
-
|
|
May 15
2025
|
Andrew Reardon CLO & Secretary |
SELL
Open market or private sale
|
Direct |
1,000
-2.95%
|
$104,000
$104.0 P/Share
|
|
May 09
2025
|
Todd C Davis Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
9,510
+1.95%
|
$989,040
$104.92 P/Share
|
|
May 09
2025
|
Octavio Espinoza Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,500
+2.64%
|
$156,000
$104.15 P/Share
|
|
Apr 01
2025
|
Stephen L Sabba Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,406
+6.88%
|
$125,112
$52.3 P/Share
|